评估在心脏骤停后和半紧急冠状动脉搭桥手术后,粉碎和非粉碎服用血小板抑制剂替卡格雷的效果和血浆浓度。

IF 2.1 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Acta cardiologica Pub Date : 2024-09-01 Epub Date: 2024-10-08 DOI:10.1080/00015385.2024.2409521
Lukas Duvillier, Carl Verhaege, Katrien M J Devreese, Sofie Gevaert, Harlinde Peperstraete
{"title":"评估在心脏骤停后和半紧急冠状动脉搭桥手术后,粉碎和非粉碎服用血小板抑制剂替卡格雷的效果和血浆浓度。","authors":"Lukas Duvillier, Carl Verhaege, Katrien M J Devreese, Sofie Gevaert, Harlinde Peperstraete","doi":"10.1080/00015385.2024.2409521","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ticagrelor, used in acute coronary syndrome (ACS), can be administered via nasogastric tube when oral intake is impossible. We investigated platelet inhibition and pharmacokinetics in resuscitated ACS patients and those undergoing semi-urgent coronary artery bypass graft (CABG) surgery. Our study aimed to assess platelet inhibition with use of the Platelet Function Analyser (PFA) and measured plasma concentrations of ticagrelor and its active metabolite in these ACS patients.</p><p><strong>Methods: </strong>We included resuscitated cardiac arrest patients (STEMI/NSTEMI) and semi-urgent CABG patients. Crushed ticagrelor tablets were administered using a nasogastric tube. PFA closure time (CT) was determined with CT longer than 113 s as reference range. Plasma concentrations of ticagrelor and its active metabolite were measured after protein precipitation, by using liquid chromatography with mass spectrometry detection.</p><p><strong>Results: </strong>In 20 resuscitated patients, 89% showed platelet inhibition at 24 h and 92% at day 4. For semi-urgent CABG patients, 85% exhibited platelet inhibition at 24 h and 84% at day 4. For ticagrelor in resuscitated patients, the median time to peak plasma concentration (Tmax) was 100 h [8; 100] for a median maximal concentration (Cmax) of 615.5 ng/mL [217.5; 1385.0]. For AR-C124910XX median Tmax was 100 h [8; 100] for a Cmax of 131.0 ng/mL [52.1; 177.7]. Among 20 patients undergoing semi-urgent CABG, Tmax for ticagrelor was 100 h [100; 100] for a median Cmax of 857.0 ng/ml [496.8; 1157.5]. For AR-C124910XX, median Tmax was 100 h [43; 100] for a Cmax of 251.0 ng/ml [173.0; 396.5].</p><p><strong>Conclusion: </strong>Crushed ticagrelor via nasogastric tube achieved targeted platelet inhibition. Pharmacokinetics aligned with previous studies.EudraCT number: 2013-004191-35; Study protocol code: AGO/2013/011; EC/2014/1061; ClinicalTrial.gov identifier: NCT02341729.</p>","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"805-812"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the effects and plasma concentration of the platelet inhibitor ticagrelor, after crushed and non-crushed intake, after cardiac arrest and after semi-urgent coronary artery bypass surgery.\",\"authors\":\"Lukas Duvillier, Carl Verhaege, Katrien M J Devreese, Sofie Gevaert, Harlinde Peperstraete\",\"doi\":\"10.1080/00015385.2024.2409521\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ticagrelor, used in acute coronary syndrome (ACS), can be administered via nasogastric tube when oral intake is impossible. We investigated platelet inhibition and pharmacokinetics in resuscitated ACS patients and those undergoing semi-urgent coronary artery bypass graft (CABG) surgery. Our study aimed to assess platelet inhibition with use of the Platelet Function Analyser (PFA) and measured plasma concentrations of ticagrelor and its active metabolite in these ACS patients.</p><p><strong>Methods: </strong>We included resuscitated cardiac arrest patients (STEMI/NSTEMI) and semi-urgent CABG patients. Crushed ticagrelor tablets were administered using a nasogastric tube. PFA closure time (CT) was determined with CT longer than 113 s as reference range. Plasma concentrations of ticagrelor and its active metabolite were measured after protein precipitation, by using liquid chromatography with mass spectrometry detection.</p><p><strong>Results: </strong>In 20 resuscitated patients, 89% showed platelet inhibition at 24 h and 92% at day 4. For semi-urgent CABG patients, 85% exhibited platelet inhibition at 24 h and 84% at day 4. For ticagrelor in resuscitated patients, the median time to peak plasma concentration (Tmax) was 100 h [8; 100] for a median maximal concentration (Cmax) of 615.5 ng/mL [217.5; 1385.0]. For AR-C124910XX median Tmax was 100 h [8; 100] for a Cmax of 131.0 ng/mL [52.1; 177.7]. Among 20 patients undergoing semi-urgent CABG, Tmax for ticagrelor was 100 h [100; 100] for a median Cmax of 857.0 ng/ml [496.8; 1157.5]. For AR-C124910XX, median Tmax was 100 h [43; 100] for a Cmax of 251.0 ng/ml [173.0; 396.5].</p><p><strong>Conclusion: </strong>Crushed ticagrelor via nasogastric tube achieved targeted platelet inhibition. Pharmacokinetics aligned with previous studies.EudraCT number: 2013-004191-35; Study protocol code: AGO/2013/011; EC/2014/1061; ClinicalTrial.gov identifier: NCT02341729.</p>\",\"PeriodicalId\":6979,\"journal\":{\"name\":\"Acta cardiologica\",\"volume\":\" \",\"pages\":\"805-812\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta cardiologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00015385.2024.2409521\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta cardiologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00015385.2024.2409521","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:用于急性冠状动脉综合征(ACS)的替卡格雷可在无法口服的情况下通过鼻胃管给药。我们研究了急性冠状动脉综合征复苏患者和接受半急诊冠状动脉旁路移植手术(CABG)患者的血小板抑制作用和药代动力学。我们的研究旨在使用血小板功能分析仪(PFA)评估血小板抑制作用,并测量这些 ACS 患者体内替卡格雷及其活性代谢物的血浆浓度:我们纳入了心脏骤停复苏患者(STEMI/NSTEMI)和半急诊 CABG 患者。使用鼻胃管给药粉碎的替卡格雷片剂。测定PFA闭合时间(CT),以CT超过113秒为参考范围。采用液相色谱-质谱检测法,在蛋白沉淀后测定血浆中替卡格雷及其活性代谢物的浓度:在 20 名复苏患者中,89% 的患者在 24 小时内出现血小板抑制,92% 的患者在第 4 天出现血小板抑制。在半急诊 CABG 患者中,85% 的患者在 24 小时后出现血小板抑制,84% 的患者在第 4 天出现血小板抑制。对于复苏患者服用替卡格雷,血浆浓度达到峰值(Tmax)的中位时间为 100 h [8; 100],最大浓度(Cmax)的中位时间为 615.5 ng/mL [217.5; 1385.0]。AR-C124910XX的中位Tmax为100小时[8;100],Cmax为131.0纳克/毫升[52.1;177.7]。在20名接受半急诊CABG的患者中,替卡格雷的Tmax为100小时[100;100],中位Cmax为857.0纳克/毫升[496.8;1157.5]。AR-C124910XX的中位Tmax为100小时[43;100],Cmax为251.0纳克/毫升[173.0;396.5]:结论:通过鼻胃管注射粉碎的替卡格雷可实现目标血小板抑制。药代动力学与之前的研究一致:研究方案代码:AGO/2013/011;EC/2014/1061;ClinicalTrial.gov标识符:NCT02341729:NCT02341729。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of the effects and plasma concentration of the platelet inhibitor ticagrelor, after crushed and non-crushed intake, after cardiac arrest and after semi-urgent coronary artery bypass surgery.

Background: Ticagrelor, used in acute coronary syndrome (ACS), can be administered via nasogastric tube when oral intake is impossible. We investigated platelet inhibition and pharmacokinetics in resuscitated ACS patients and those undergoing semi-urgent coronary artery bypass graft (CABG) surgery. Our study aimed to assess platelet inhibition with use of the Platelet Function Analyser (PFA) and measured plasma concentrations of ticagrelor and its active metabolite in these ACS patients.

Methods: We included resuscitated cardiac arrest patients (STEMI/NSTEMI) and semi-urgent CABG patients. Crushed ticagrelor tablets were administered using a nasogastric tube. PFA closure time (CT) was determined with CT longer than 113 s as reference range. Plasma concentrations of ticagrelor and its active metabolite were measured after protein precipitation, by using liquid chromatography with mass spectrometry detection.

Results: In 20 resuscitated patients, 89% showed platelet inhibition at 24 h and 92% at day 4. For semi-urgent CABG patients, 85% exhibited platelet inhibition at 24 h and 84% at day 4. For ticagrelor in resuscitated patients, the median time to peak plasma concentration (Tmax) was 100 h [8; 100] for a median maximal concentration (Cmax) of 615.5 ng/mL [217.5; 1385.0]. For AR-C124910XX median Tmax was 100 h [8; 100] for a Cmax of 131.0 ng/mL [52.1; 177.7]. Among 20 patients undergoing semi-urgent CABG, Tmax for ticagrelor was 100 h [100; 100] for a median Cmax of 857.0 ng/ml [496.8; 1157.5]. For AR-C124910XX, median Tmax was 100 h [43; 100] for a Cmax of 251.0 ng/ml [173.0; 396.5].

Conclusion: Crushed ticagrelor via nasogastric tube achieved targeted platelet inhibition. Pharmacokinetics aligned with previous studies.EudraCT number: 2013-004191-35; Study protocol code: AGO/2013/011; EC/2014/1061; ClinicalTrial.gov identifier: NCT02341729.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta cardiologica
Acta cardiologica 医学-心血管系统
CiteScore
2.50
自引率
12.50%
发文量
115
审稿时长
2 months
期刊介绍: Acta Cardiologica is an international journal. It publishes bi-monthly original, peer-reviewed articles on all aspects of cardiovascular disease including observational studies, clinical trials, experimental investigations with clear clinical relevance and tutorials.
期刊最新文献
The association between peak tricuspid regurgitation velocity and 1-year heart failure readmission in hospitalised patients with heart failure with preserved ejection fraction. Left ventricular myocardial deformation in patients on maintenance haemodialysis. Accessory mitral valve tissue causing left ventricular outflow obstruction. Multimodality imaging for the diagnosis of right atrial capillary haemangioma. Association between the triglyceride-glucose index and the severity of coronary artery disease in patients with type 2 diabetes mellitus and coronary artery disease: a retrospective study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1